At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 682 enrolled
Drug / intervention
SB-742457 15mg +3 moredrug
Likely dose
SB-742457 15mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-moderate Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating SB-742457 15mg, SB-742457 35mg, and 2 other interventions for Alzheimer's Disease. Completed, enrolled 682 participants across 102 sites in 9 countries.
Detailed Summary
The study is designed to investigate the safety and efficacy of SB-742457 when added to stable donepezil treatment in subjects with mild-to-moderate Alzheimer's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesArgentina, Australia, Canada, Chile, Czechia, Germany, Italy, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2008
First PostedJul 2008
Primary CompletionMay 2010
Study CompletionNov 2010
TodayJul 2026
First PostedJul 4, 2008
Enrollment StartJul 1, 2008
Primary CompletionMay 21, 2010
Study CompletionNov 16, 2010
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 18.0 years ago
Interventions
SB-742457 15mgdrug
SB-742457 - 15mg added to existing donepezil treatment
SB-742457 35mgdrug
SB-742457 - 35mg added to existing donepezil
Placebodrug
Placebo added to existing donepezil
donepezil 5-10mgdrug
existing donepezil treatment